A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Clinical trial NCT02267863 · TERMINATED

Trial details

NCT number: NCT02267863
Sponsor: Aptose Biosciences Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myelogenous Leukemia in Relapse Acute Myelogenous Leukemia, Relapsed, Adult Acute Myelogenous Leukemia, Adult Acute Myelogenous Leukemia High Risk Myelodysplasia

Start date: 2014-10-01
Primary completion: 2021-09-01
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.